{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bioequivalence+Study+in+Healthy+Subjects&page=4", "query": { "condition": "Bioequivalence Study in Healthy Subjects", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 416, "total_pages": 42, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bioequivalence+Study+in+Healthy+Subjects&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bioequivalence+Study+in+Healthy+Subjects&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T08:39:52.211Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00649038", "title": "Fed Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg", "type": "DRUG" }, { "name": "Lotensin HCT® Tablets 20 mg/25 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mylan Pharmaceuticals Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2002-12", "completion_date": "2002-12", "has_results": false, "last_update_posted_date": "2024-04-24", "last_synced_at": "2026-10-07T08:39:52.211Z", "location_count": 1, "location_summary": "Fargo, North Dakota", "locations": [ { "city": "Fargo", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00649038" }, { "nct_id": "NCT04421885", "title": "Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference", "type": "DRUG" }, { "name": "Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Test", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Spero Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 36, "start_date": "2020-06-01", "completion_date": "2020-07-29", "has_results": false, "last_update_posted_date": "2020-08-12", "last_synced_at": "2026-10-07T08:39:52.211Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04421885" }, { "nct_id": "NCT01906125", "title": "A Study To Establish The Equivalence Of 2 Palbociclib (PD-0332991) Formulations To The Intended Final Market Product", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "palbociclib capsule: phase 1 and 2 studies", "type": "DRUG" }, { "name": "Palbociclib capsule: phase 3 studies", "type": "DRUG" }, { "name": "Palbociclib capsule: ICH", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 73, "start_date": "2013-09", "completion_date": "2014-01", "has_results": false, "last_update_posted_date": "2014-01-20", "last_synced_at": "2026-10-07T08:39:52.211Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01906125" }, { "nct_id": "NCT00865410", "title": "A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fasting Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Abrika Bupropion 150 mg Extended-Released Tablet", "type": "DRUG" }, { "name": "Wellbutrin SR® 150 mg Extended-Release Tablet, single dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actavis Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 26, "start_date": "2004-08", "completion_date": "2004-09", "has_results": false, "last_update_posted_date": "2010-08-16", "last_synced_at": "2026-10-07T08:39:52.211Z", "location_count": 1, "location_summary": "Fort Myers, Florida", "locations": [ { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00865410" }, { "nct_id": "NCT01981278", "title": "A Study to Assess Bioequivalence of a New Tapentadol Extended-Release 250-mg Tablet With Respect to a Tapentadol Extended-Release 250-mg Tablet in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Tapentadol ER 250-mg TRF tablet", "type": "DRUG" }, { "name": "Tapentadol ER 250-mg PR2 tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "19 Years to 55 Years" }, "enrollment_count": 63, "start_date": "2010-07", "completion_date": "2010-08", "has_results": false, "last_update_posted_date": "2013-11-14", "last_synced_at": "2026-10-07T08:39:52.211Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01981278" }, { "nct_id": "NCT04536415", "title": "Bioequivalence Study of Oseltamivir Phosphate and TAMIFLU Under Fed Condition in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Bioequivalence" ], "interventions": [ { "name": "Oseltamivir Phosphate 75 mg capsules", "type": "DRUG" }, { "name": "Tamiflu capsules 75 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Austarpharma, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 96, "start_date": "2020-08-25", "completion_date": "2020-08-27", "has_results": false, "last_update_posted_date": "2023-02-02", "last_synced_at": "2026-10-07T08:39:52.211Z", "location_count": 1, "location_summary": "Edison, New Jersey", "locations": [ { "city": "Edison", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04536415" }, { "nct_id": "NCT00649935", "title": "Fed Study of Azithromycin Tablets 600 mg to Zithromax® Tablets 600 mg", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Azithromycin Tablets 600 mg", "type": "DRUG" }, { "name": "Zithromax® Tablets 600 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mylan Pharmaceuticals Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2005-05", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2024-04-24", "last_synced_at": "2026-10-07T08:39:52.211Z", "location_count": 1, "location_summary": "Morgantown, West Virginia", "locations": [ { "city": "Morgantown", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00649935" }, { "nct_id": "NCT02074553", "title": "A Cross-over Study Examining the Bioequivalence of 3 Test Formulations to a Reference Formulation of Alectinib (RO5424802) in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "Ro542-4802/F03 (Reference)", "type": "DRUG" }, { "name": "Ro542-4802/F07 (Test)", "type": "DRUG" }, { "name": "Ro542-4802/F08 (Test)", "type": "DRUG" }, { "name": "Ro542-4802/F14 (Test)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 97, "start_date": "2014-02", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2023-12-11", "last_synced_at": "2026-10-07T08:39:52.211Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02074553" }, { "nct_id": "NCT00649272", "title": "Fasting Study of Oxybutynin Chloride Extended-Release Tablets 15 mg and Ditropan XL® Tablets 15 mg", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Oxybutynin Chloride Extended-Release Tablets, 15 mg", "type": "DRUG" }, { "name": "Ditropan XL® Extended-release tablets, 15 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mylan Pharmaceuticals Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2006-01", "completion_date": "2006-02", "has_results": false, "last_update_posted_date": "2024-04-24", "last_synced_at": "2026-10-07T08:39:52.211Z", "location_count": 1, "location_summary": "Fargo, North Dakota", "locations": [ { "city": "Fargo", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00649272" }, { "nct_id": "NCT00863902", "title": "A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Non-fasting Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Cetirizine Hydrochloride 10 mg tablets, single dose", "type": "DRUG" }, { "name": "Zyrtec® 10 mg tablets, single dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actavis Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2006-08", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2010-08-16", "last_synced_at": "2026-10-07T08:39:52.211Z", "location_count": 1, "location_summary": "Morrisville, North Carolina", "locations": [ { "city": "Morrisville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00863902" } ] }